Clinical Trials of Ticlopidine in Patients with Intermittent Claudication
Atherosclerosis is the main pathophysiologic process behind peripheral arterial disease (PAD).1 Like other atherosclerotic manifestations, PAD is more common in old people than young and more common in men than women. The clinical spectrum of PAD ranges from an asymptomatic stage with weak leg arterial pulsations, a femoral bruit, or an abnormal systolic arm-ankle pressure gradient, to a symptomatic stage with intermittent claudication, rest pain, and gangrene. Depending on different clinical criteria and varying methods of assessing leg blood flow, the prevalence of PAD varies from one study to another. Several publications have presented prevalence estimates of intermittent claudication as being 2% in middle-aged men and 1% in middle-aged women.2–4 Study findings by Reunanen et al.2 support the clinical experience that PAD is becoming more common in women. Among 30–39-year-olds in that study, the prevalence of intermittent claudication was twice as high in women as in men.
KeywordsPlacebo Cholesterol Ischemia Diarrhea Smoke
Unable to display preview. Download preview PDF.
- 1.Strandness DE Jr. Peripheral Arterial Disease. Boston, Little Brown, 1969.Google Scholar
- 4.Isacsson S-O. Venous occlusion plethysmography in 55-year-old men. A population study in Malmö, Sweden (thesis). Acta Med Scand 1972; 191: 537.Google Scholar
- 9.Kannel WB, Shurtleff D. The natural history of arteriosclerosis obliterans. Cardiovasc Clin 1971; 37: 3.Google Scholar
- 11.Silbert S, Zazeela H. Prognosis in arteriosclerotic peripheral vascular disease. JAMA 1958; 166: 186.Google Scholar
- 15.Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242: 2562.Google Scholar
- 16.Coronary Heart Disease—Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 351–374.CrossRefGoogle Scholar
- 21.Ellis DJ. Treatment of intermittent claudication with ticlopidine. Abstract addendum. International Committee on Thrombosis and Haemostasis 32nd Annual Meeting and the Mediterranean League Against Thromboembolic Diseases, 9th Congress. Jerusalem, June 1–6, 1986.Google Scholar
- 22.Cloarec M, Caillard PH, Mouren X. Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs. Thromb Res 1986; 6: 160.Google Scholar
- 24.Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Heamost 1989; 62 (2): 681–685.Google Scholar